

**Anti-FGFR4 / CD334 Reference Antibody (U3-1784)**  
**Recombinant Antibody**  
**Catalog # APR10113****Specification**

---

**Anti-FGFR4 / CD334 Reference Antibody (U3-1784) - Product Information**

Application	FC, E, FTA
Primary Accession	<a href="#">P22455</a>
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	150 KDa

**Anti-FGFR4 / CD334 Reference Antibody (U3-1784) - Additional Information****Target/Specificity**  
FGFR4 / CD334**Endotoxin**  
< 0.001EU/ µg,determined by LAL method.**Conjugation**  
Unconjugated**Expression system**  
CHO Cell**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Storage**  
-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.**Anti-FGFR4 / CD334 Reference Antibody (U3-1784) - Protein Information****Name** FGFR4**Synonyms** JTK2, TKF**Function**  
Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays a role in the regulation of cell proliferation, differentiation and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. Required for normal down- regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. Phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the

production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Promotes SRC-dependent phosphorylation of the matrix protease MMP14 and its lysosomal degradation. FGFR4 signaling is down-regulated by receptor internalization and degradation; MMP14 promotes internalization and degradation of FGFR4. Mutations that lead to constitutive kinase activation or impair normal FGFR4 inactivation lead to aberrant signaling.

#### Cellular Location

Cell membrane; Single-pass type I membrane protein. Endosome. Endoplasmic reticulum. Note=Internalized from the cell membrane to recycling endosomes, and from there back to the cell membrane

#### Tissue Location


Expressed in gastrointestinal epithelial cells, pancreas, and gastric and pancreatic cancer cell lines

### Anti-FGFR4 / CD334 Reference Antibody (U3-1784) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


### Anti-FGFR4 / CD334 Reference Antibody (U3-1784) - Images



Anti-FGFR4 / CD334 Reference Antibody (U3-1784) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-FGFR4 / CD334 Reference Antibody (U3-1784) is more than 99.1% ,determined by SEC-HPLC.



Immobilized human FGFR4 FC at 2 µg/mL can bind Anti-FGFR4 / CD334 Reference Antibody (U3-1784)  $EC_{50}=0.6894$  µg/mL